The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Saturday, 21 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor UK News

Cancer 'Sponge' Tests Could Reach More NHS Patients

By The Daily Byte ·16 Nov 2026 ·4 min read
The Cytosponge capsule on a thread next to the expanded black sponge used to collect cells from the oesophagus

People in England with bad and persistent indigestion could soon be offered a quick "sponge in the gullet" test at their GP surgery to check for early signs of cancer of the food pipe, under new draft guidance from the National Institute for Health and Care Excellence (NICE) published on 16 November.

The test takes only a few minutes and is far less invasive than the hospital endoscopy it would partly replace. It can be carried out in GP surgeries and community diagnostic centres, with no sedation and no camera, and it is aimed in particular at people whose indigestion is linked to reflux disease, in which stomach acid washes back up into the food pipe.

How the sponge test works

For the test, the patient swallows a small dissolving capsule attached to a fine thread. Once the capsule reaches the stomach it dissolves and releases a tiny sponge, which is then gently pulled back up through the gullet and out of the mouth by the doctor. As it travels, the sponge collects cells from the lining of the oesophagus, and those cells can then be examined for changes that might point to cancer.

NICE's independent committee has recommended two capsule sponge tests: Cytosponge, made by Medtronic, and EndoSign, made by Cyted Health. The recommendations are the first to be produced through the National HealthTech Access Programme, a new approach designed to identify high-impact medical technologies that, if recommended by NICE, will be funded by the NHS and made consistently available to all eligible patients across the country.

What the test can detect

The sponge tests can help detect oesophageal cancer and Barrett's oesophagus, a condition in which the cells lining the gullet have started to change after long exposure to stomach acid. Barrett's oesophagus increases the risk of cancer in the long term, and it is thought that between one and two adults in every 100 has the condition. Most will not go on to develop cancer, but demand for NHS endoscopy is high, meaning some people with the condition are not checked as often as recommended.

The draft guidance would also give people already diagnosed with Barrett's oesophagus another option for monitoring their condition, with the capsule sponge tests used as part of a surveillance programme to check periodically for cell changes that may indicate oesophageal cancer.

Professor Jonathan Benger, chief executive of NICE, said the sponge tests offer a "quick and less invasive" way to detect concerning changes, helping to identify people who should go on to have further tests and treatment. Professor Peter Johnson, national clinical director for cancer at NHS England, said thousands of people had already benefited from the test through pilots the NHS has been running. "Thousands have already benefited from this incredibly efficient test through pilots we have been running, so it's fantastic it is now being considered for roll out across the country," he said.

He added that an easier way to check for changes in the lining of the oesophagus "can make a big difference for patients, reducing the need for more complicated endoscopy tests and helping the NHS free up resources to find cancers at an earlier stage".

What happens next

The guidance is still in draft, and the final recommendations will not be made until the new year. Comments can be made on the draft through the NICE website until 7 December 2026, and the committee will meet again on 16 December to consider the responses before issuing final draft guidance during January 2027. If the recommendations are confirmed in final guidance due during February 2027, the NHS in England will be required to begin delivering the technology, including specialist staff training across the country, when a capsule sponge test is considered the most suitable option for the person.

The guidance also carries an important caution. No diagnostic test, including endoscopy, identifies every case, and NICE says people who receive a clear result from a sponge test should still be monitored over the long term rather than being discharged and forgotten. A positive sponge test result would still mean referral for further tests and treatment.

The sponge tests are already available in some parts of the country. If the draft guidance is confirmed, many more people with persistent indigestion could be offered the test at their GP surgery, with those whose samples show concerning changes referred on for further investigation.

Sources: NICE; BBC News, via Everywhere News.